Videos

The co-director of the Neurological Clinical Research Institute at Massachusetts General Hospital offered her perspective on the expected developments for ALS care in next few years, and where AMX0035 might fit in that landscape.

The chief research officer and epilepsy specialist at Cleveland Clinic detailed her most recent findings on the cost-effectiveness of epilepsy surgery for drug-resistant temporal lobe epilepsy.

The director of the Lou Ruvo Center for Brain Health and neurologist at Cleveland Clinic discussed the potential of aducanumab and the amyloid theory in patients with Alzheimer disease.

The vice president of science and medical at Dreem discussed how the company’s headband device stacked up against polysomnography for sleep monitoring.

Neurology News Network for the week ending August 15, 2020.

The director of the Center for Neurological Restoration at Cleveland Clinic describes the greatest unmet needs in Parkinson disease research.

The vice president of science and medical at Dreem offered an overview of the hardware that makes up the Dreem Headband and how it was developed to monitor sleep.

The postdoctoral fellow at the University of Miami Miller School of Medicine detailed the role that increased APOE ε4 expression can have on future research and clinical care.

The co-director of the Neurological Clinical Research Institute at Massachusetts General Hospital spoke to findings of the phase 2 CENTAUR trial of AMX0035 in amyotrophic lateral sclerosis.

The medical director of the New England Institute for Neurology and Headache and chief medical officer of the New England Institute for Clinical Research detailed the end points and long-term goals of the phase 2 JUNIPER upper limb spasticity trial.

The director emeritus of the Lou Ruvo Center for Brain Health at Cleveland Clinic and vice chair of the Department of Brain Health at the University of Nevada–Las Vegas discussed the leading challenges for those with Alzheimer disease.

Neurology News Network for the week ending August 8, 2020.

The director of the Center for Neurological Restoration at Cleveland Clinic detailed the recent technological and therapeutic innovations and their advantages in treating Parkinson disease.

The director of the Sagol Center for Hyperbaric Medicine and Research at Yitzhak Shamir Medical Center discussed the history of the research and offered insight into the attempt to regenerate injured tissue in the brain.

The co-director of the Neurological Clinical Research Institute at Massachusetts General Hospital spoke to the need for more collaborative efforts in ALS research.

The director of the Memory Disorders Program and professor of neurology at Georgetown University Medical Center detailed the phase 2 study findings of nilotinib in patients with Alzheimer disease.

The postdoctoral fellow at the University of Miami Miller School of Medicine detailed her study presented at AAIC 2020 that examined Alzheimer risk associated with APOE ε4 in different genetic populations.

Neurology News Network for the week ending August 1, 2020.

The co-director of the Neurological Clinical Research Institute at Massachusetts General Hospital discussed how the investigational agent might fit into the landscape of amyotrophic lateral sclerosis treatment as it progresses through the pipeline.

The director of the Center for Neurological Restoration at Cleveland Clinic details the direction of clinical research for Parkinson disease and efforts that are being made to alleviate quality of life issues for those with the disease.

The director emeritus of the Lou Ruvo Center for Brain Health at Cleveland Clinic and vice chair of the Department of Brain Health at the University of Nevada­–Las Vegas gives his thoughts on the latest aducanumab update and its potential as a treatment for Alzheimer disease.

The medical director of the New England Institute for Neurology and Headache and chief medical officer of the New England Institute for Clinical Research detailed the lack awareness and options for those who suffer from upper limb spasticity following a stroke.

The director of the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed the benefit that physicians and patients can be provided by highly selective S1P modulators in MS treatment.

The vice president of AstraZeneca’s Cardiovascular and Metabolic Diseases Portfolio detailed the results from the phase 3 THALES trial, and where ticagrelor stands among other FDA approved stroke treatments.

Neurology News Network for the week ending July 25, 2020.

The director emeritus of the Lou Ruvo Center for Brain Health at Cleveland Clinic and vice chair of the Department of Brain Health at the University of Nevada-Las Vegas, details trends in Alzheimer disease research over the past few years.

The assistant professor of neurosurgery at Yale School of Medicine discussed what doors have been opened by a recent study of the cell death process she and colleagues conducted.

The director of the Mellen Center for MS Treatment and Research at Cleveland Clinic spoke to the development of the sphingosine-1-phosphate modulator class in MS treatment.

The director of the Center for Neurological Restoration at Cleveland Clinic discussed the importance of raising awareness of Parkinson disease on World Brain Day, highlighting the magnitude of the disease.

The director of the Neurology Residency Program at Weill Cornell Medicine highlighted some of the differences in types of headaches that patients with COVID-19 experience, as well as overall takeaways from the pandemic itself.